Teva Pharmaceutical Industries Limited Sponsored ADR Aktie News

TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows:

Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceuticals industry.

Teva Pharmaceutical Industries Limited ( TEVA ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Welcome to the Jefferies London Healthcare Conference. My name is Dennis Din...

Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business

Quarterly-filed Form 13Fs can clue investors into which stocks and trends are piquing the interest of Wall Street's brightest money managers. Billionaire Stanley Druckenmiller dumped his fund's holdings in artificial intelligence (AI) stocks Nvidia and Palantir -- and profit-taking may not tell the full story.

Teva Pharmaceutical Industries Limited ( TEVA ) UBS Global Healthcare Conference 2025 November 10, 2025 8:45 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-releas...

The big drugmaker unveiled its latest set of quarterly figures. Thanks to healthy rises in sales of key drugs, its revenue and profitability rose admirably.